GLP-1 receptor agonist: difference between revisions
Diff·revision 27 → 28·03:13, 28 Jul 2025
Difference between revision 27 and revision 28 of GLP-1 receptor agonist. 7 lines changed; the page grew by 1,226 bytes.
| Revision 27 — 16:46, 6 Jul 2025 ComparisonCato (talk) copyedit 9,922 bytes +164 | Revision 28 — 03:13, 28 Jul 2025 UACR_Ulric (talk) give the INN alongside the trade name at first mention 11,148 bytes +1,226 | ||
|---|---|---|---|
| 60 | Loss of lean mass accompanies the loss of fat mass, in a proportion broadly comparable with that seen in other forms of substantial caloric restriction. Whether this proportion is materially different from that of diet-induced weight loss is disputed, and the trials were not designed to settle it.{{r|wilding2021}} | 60 | Loss of lean mass accompanies the loss of fat mass, in a proportion broadly comparable with that seen in other forms of substantial caloric restriction. Whether this proportion is materially different from that of diet-induced weight loss is disputed, and the trials were not designed to settle it.{{r|wilding2021}} |
| 61 | 61 | ||
| + | 62 | == Material obtained outside licensed supply == | |
| + | 63 | Peptides of this class are synthesised and sold as research chemicals by a large number of organisations, and the resulting material is not a medicine: it is not manufactured under a marketing authorisation, is not released against a pharmacopoeial specification, and carries no regulatory assurance of identity, purity, sterility or fill mass.{{r|usp1503}} | |
| + | 64 | ||
| + | 65 | Documentation supplied with such material varies from a full lot-specific [[Certificate of analysis|certificate of analysis]] with named methods to a single unattributed purity figure. A purity figure alone is not sufficient to characterise a peptide: without a [[Peptide content|peptide content]] determination and a water figure, the mass of active substance in a vial cannot be calculated, and a nominal 5 mg vial may contain substantially less. [[Underfilling|Underfilling]] is documented in independently tested material.{{r|reports}} | |
| + | 66 | ||
| 62 | == References == | 67 | == References == |
| 63 | {{reflist}} | 68 | {{reflist}} |
| ⋮ | ⋮ | ||
| 68 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). DOI:10.1056/NEJMoa2307563. PMID 37952131.</ref> | 73 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). DOI:10.1056/NEJMoa2307563. PMID 37952131.</ref> |
| 69 | <ref name="frias2023">Frías JP, Hsia S, Eyde S, et al. "Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a phase 2 randomised trial." ''The Lancet'' 402(10400):472–483 (2023). PMID 37369232.</ref> | 74 | <ref name="frias2023">Frías JP, Hsia S, Eyde S, et al. "Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a phase 2 randomised trial." ''The Lancet'' 402(10400):472–483 (2023). PMID 37369232.</ref> |
| + | 75 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| + | 76 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | |
| 70 | 77 | ||
| 71 | == Further reading == | 78 | == Further reading == |